Latest News
Jade Biosciences, Inc.
- Jade Biosciences delays Phase 3 trial start for JADE101
- About 169,000 Americans have IgA kidney disease. Jade expects its trial to start this quarter.
- Wedbush reiterates Jade Biosciences stock rating on preclinical data By Investing.com
- H.C. Wainwright reiterates Jade Biosciences stock rating at buy By Investing.com
- Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
- Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis - Slideshow
Headlines from the last 30 days, linking to the original publishers. See all market news →